StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report sent to investors on Friday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Up 3.6 %

Shares of NASDAQ:CHEK opened at $1.15 on Friday. Check-Cap has a 12 month low of $1.10 and a 12 month high of $3.94. The firm has a market cap of $6.73 million, a P/E ratio of -0.38 and a beta of 0.39. The company’s 50-day moving average price is $1.55 and its two-hundred day moving average price is $1.91.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.